Crism completes manufacture of first ChemoSeed chemical batch.
Crism Therapeutics said on Wednesday that it has completed manufacture of the first clinical batch of its ChemoSeed therapy for use in a phase two trial in glioblastoma, while pushing back the expected timing of first patient dosing to the first half of 2026.
Airtel Mobile Commerce N.V. (DI)
25 March 2026 13:00:22
Source: Sharecast
The AIM-traded clinical-stage drug delivery company said its US-based manufacturing partner, ProMed Pharma, had produced the batch in line with current Good Manufacturing Practice standards.
It said the product would now undergo sterilisation and release testing before being made available for use in the trial.
Crism added that it was continuing to work with its contract research organisation, Aixial, and the initial trial site to complete the remaining activation steps required to begin dosing patients.
While the company said progress towards the start of the trial was advancing at pace, it noted that the precise timing of first patient dosing remained uncertain and had thus extended its guidance to the first half of 2026.
Crism said it remained focussed on initiating the study as soon as possible and would provide further updates once the trial begins.
At 1150 GMT, shares in Crism Therapeutics Corporation were down 5.88% at 12p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
